Analysts Set HCA Healthcare, Inc. (NYSE:HCA) PT at $534.41

HCA Healthcare, Inc. (NYSE:HCA – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the twenty-four brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $523.0909.

HCA has been the subject of several recent analyst reports. Robert W. Baird decreased their price target on HCA Healthcare from $450.00 to $442.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. Jefferies Financial Group restated a “buy” rating and issued a $525.00 price objective on shares of HCA Healthcare in a report on Friday. Mizuho upped their price objective on HCA Healthcare from $540.00 to $585.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Leerink Partners reduced their target price on HCA Healthcare from $573.00 to $500.00 and set an “outperform” rating for the company in a report on Monday. Finally, UBS Group upped their target price on HCA Healthcare from $598.00 to $635.00 and gave the company a “buy” rating in a report on Monday, February 23rd.

View Our Latest Stock Analysis on HCA

Insider Buying and Selling

In other HCA Healthcare news, SVP Jennifer Berres sold 8,020 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $514.58, for a total value of $4,126,931.60. Following the completion of the sale, the senior vice president owned 11,993 shares in the company, valued at approximately $6,171,357.94. This trade represents a 40.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael R. Mcalevey sold 1,694 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $533.37, for a total value of $903,528.78. Following the completion of the sale, the executive vice president owned 8,853 shares of the company’s stock, valued at $4,721,924.61. This represents a 16.06% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 15,214 shares of company stock valued at $7,797,595. 1.50% of the stock is currently owned by company insiders.

Institutional Trading of HCA Healthcare

Hedge funds have recently modified their holdings of the company. Palisade Asset Management LLC bought a new position in shares of HCA Healthcare during the 3rd quarter worth approximately $26,000. Holos Integrated Wealth LLC bought a new position in shares of HCA Healthcare during the 4th quarter worth approximately $29,000. Ares Financial Consulting LLC bought a new position in shares of HCA Healthcare during the 4th quarter worth approximately $31,000. Harbor Capital Advisors Inc. lifted its position in shares of HCA Healthcare by 82.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 75 shares of the company’s stock worth $32,000 after buying an additional 34 shares during the period. Finally, JPL Wealth Management LLC bought a new position in shares of HCA Healthcare during the 3rd quarter worth approximately $33,000. Institutional investors own 62.73% of the company’s stock.

HCA Healthcare Price Performance

Shares of HCA opened at $446.38 on Friday. HCA Healthcare has a 12 month low of $326.14 and a 12 month high of $556.52. The company has a market cap of $99.80 billion, a P/E ratio of 15.35, a PEG ratio of 1.45 and a beta of 1.36. The stock has a fifty day moving average price of $503.58 and a 200 day moving average price of $486.01.

HCA Healthcare (NYSE:HCA – Get Free Report) last released its quarterly earnings results on Friday, April 24th. The company reported $7.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.19 by ($0.04). HCA Healthcare had a negative return on equity of 295.93% and a net margin of 8.89%.The business had revenue of $19.11 billion during the quarter, compared to the consensus estimate of $19.09 billion. During the same period in the previous year, the company posted $6.45 EPS. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. As a group, research analysts anticipate that HCA Healthcare will post 30.15 earnings per share for the current year.

HCA Healthcare Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 16th will be issued a dividend of $0.78 per share. This represents a $3.12 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Tuesday, June 16th. HCA Healthcare’s dividend payout ratio is currently 10.99%.

More HCA Healthcare News

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: Management reaffirmed FY2026 guidance and expects 2%–3% volume growth while acknowledging headwinds, which supports the company’s forward earnings outlook. HCA projects 2%-3% volume growth
• Positive Sentiment: HCA says improvements in its revenue‑cycle operations are boosting cash collections and helping offset rising denials/underpayments — a near‑term margin and cash‑flow positive. Revenue cycle paying dividends
• Positive Sentiment: Leadership hire: Cynthia Cifuentes‑Finkel will become SVP of Marketing & Corporate Affairs (effective June 8), adding senior marketing/communications capacity ahead of growth initiatives. HCA names new SVP
• Neutral Sentiment: Local operations: a new HCA Florida Gainesville hospital is preparing to open next month — incremental local growth but limited immediate impact on enterprise results. Gainesville hospital opening
• Neutral Sentiment: Market commentary pieces and index signals are discussing healthcare positioning; useful for macro context but not company‑specific catalysts. Market update
• Negative Sentiment: Multiple analysts reduced price targets and trimmed forecasts after Q1 results (despite an in‑line EPS), signaling more cautious near‑term sentiment. Firms lowering targets include Stephens, Oppenheimer, TD Cowen, Leerink, RBC and Truist. Analysts slash forecasts
• Negative Sentiment: Q1 dynamics: EPS roughly in‑line but seasonal volume softness, shifting payer mix and projected ACA/exchange pressures (company cites a $600M–$900M headwind range) are weighing on near‑term revenue and margin expectations. Q1 deep dive
• Negative Sentiment: Financing: HCA filed a proposed public offering of senior notes to raise proceeds for general corporate purposes (may include refinancing). New debt issuance could modestly pressure credit metrics depending on size and terms. Proposed senior notes offering

HCA Healthcare Company Profile

(Get Free Report)

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.

See Also

• Five stocks we like better than HCA Healthcare